QR-koda

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review

Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by e...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Xiangyun You, Shan Huang, Xin’an Wang, Cheng Yi, Niandong Gong, Junfeng Yu, Chengdang Xu, Zhendong Xiang
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Frontiers Media S.A. 2023-04-01
Ráidu:Frontiers in Endocrinology
Fáttát:
bipolar androgen therapy
testosterone
castration-resistant prostate cancer
abiraterone
enzalutamide
Liŋkkat:https://www.frontiersin.org/articles/10.3389/fendo.2022.1125838/full
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid